CytomX Therapeutics, Inc. logo CTMX - CytomX Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 17
HOLD 4
SELL 0
STRONG
SELL
0
| PRICE TARGET: $11.25 DETAILS
HIGH: $16.00
LOW: $6.00
MEDIAN: $11.50
CONSENSUS: $11.25
UPSIDE: 242.99%
AlphaQuality

AlphaQuality

Quantitative six-pillar business-quality grade

High-Growth Software

AlphaQuality — archetype-weighted quantitative grade

F 26.3 / 100 pillar composite

Composite Grade

Composite of six pillars weighted for high-growth software businesses. Purely quantitative — the six pillars score only reported financials, no analyst input.

⚠ 4 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.

Grade overrides the 26.3 pillar composite because hard gates always win. Use the pillar breakdown below to see where the underlying numbers sit.

Profitability

Weight: 15%
D- 30.0
  • 5yr Avg ROIC -53.5% 0/100
  • Operating Margin Trend +77.20 pp/yr 100/100
Contributes 4.5 pts toward composite.

Capital Efficiency

Weight: 15%
F 0.0
  • 5yr Share-Count CAGR 24.5% 0/100
Contributes 0.0 pts toward composite.

Growth Quality

Weight: 35%
C- 44.9
  • 5yr Revenue CAGR 2.2% 38/100
  • Revenue-Growth Years (5) 3/5 60/100
Contributes 15.7 pts toward composite.

Cash Generation

Weight: 20%
F 0.0
  • 5yr FCF Margin -150.7% 0/100
  • 5yr FCF/NI Conversion -2.72x 0/100
Contributes 0.0 pts toward composite.

Balance Sheet

Weight: 10%
C- 44.0
  • Net Debt / EBITDA 10.00x 0/100
  • Interest Coverage (EBIT/Int) 30.00x 100/100
  • Altman Z-Score 2.48 56/100
Contributes 4.4 pts toward composite.

Stability

Weight: 5%
D 33.3
  • Negative-Revenue Years (5) 2/5 60/100
  • Piotroski F-Score 1 11/100
Contributes 1.7 pts toward composite.

Guru Flow

Curated superinvestor sentiment — not part of the AlphaQuality grade.
Dumping

0 of 2 gurus held; 2 full exits.

Holders
0 -2
Avg Δ position
New buys
0
Full exits
2
As of Q2 2026
How this is calculated

AlphaQuality grades six pillars from 0-100 and weights each by archetype:

  • Profitability (15%) — 5yr Avg ROIC, Operating Margin Trend
  • Capital Efficiency (15%) — 5yr Share-Count CAGR
  • Growth Quality (35%) — 5yr Revenue CAGR, Revenue-Growth Years (5)
  • Cash Generation (20%) — 5yr FCF Margin, 5yr FCF/NI Conversion
  • Balance Sheet (10%) — Net Debt / EBITDA, Interest Coverage (EBIT/Int), Altman Z-Score
  • Stability (5%) — Negative-Revenue Years (5), Piotroski F-Score

The six pillars read only reported financial-statement fields — no analyst targets or consensus ratings. The archetype that picks which pillar formulas apply is not fully price-free, though: it can route a company to the distressed/ungradable archetype based on price vs. its 52-week high, and beta affects one classification check. A minimum of 5 fiscal years of audited statements is required. Insurers and banks are graded on their own methodology — insurers on loss ratio, its trend and stability, and premiums-to-surplus; banks on the efficiency ratio, its trend and stability, and equity-to-assets — rather than on industrial margin/ROIC signals. Distressed, highly leveraged infrastructure, asset-manager, and other financial businesses are declared ungradable rather than forced into a numeric score.